One of two of Opthea's phase III trials for a common eye disease has failed to meet its objectives, casting doubts on the ...

Patients with diabetic macular edema previously treated with a ranibizumab biosimilar in India experience comparable safety ...

The investigators retrospectively evaluated 126 consecutive treatment-naïve nAMD patients (126 eyes) who received a loading ...

On March 14, 2025, the U.S. Court of Appeals for the Federal Circuit affirmed the District Court for the Northern District of West Virginia’s ...

The introduction of biosimilars in the treatment of age-related macular degeneration (AMD) is raising concerns among ...

The ASX has been up 0.62% at 7,837 points, following Wall Street’s Friday lead. It’s a sea of green today and Materials has ...

Regeneron (REGN) faces a 3% stock drop after losing an appeals case over its Eylea drug patents against Amgen (AMGN).

The retina is a layered structure that lines the inner surface of the eye. It consists of layers of neurons: light-sensitive photoreceptor cells, bipolar cells, horizontal cells, amacrine cells ...

D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and ...

4FRONT-1 is a Phase 3 multicenter, randomized, double-masked, aflibercept 2 mg (Q8W) comparator-controlled study of intravitreal 4D-150 in wet AMD. The primary endpoint is non-inferiority in the mean ...

The DAYBREAK study includes tarcocimab in a second investigational arm against active comparator aflibercept and incorporates learnings from prior pivotal trials of tarcocimab to maximize the ...

4FRONT-1 is a Phase 3 multicenter, randomized, double-masked, aflibercept 2 mg (Q8W) comparator-controlled study of intravitreal 4D-150 in wet AMD. The primary endpoint is non-inferiority in the mean ...